If wishes were horses, companies would IPO
This article was originally published in Scrip
Chairing a debate on the attractiveness of biotech IPOs, co-hosted by One Nucleus, the Cambridge-London biotech network , and Scrip Intelligence, it was surprising to see how divergent the views of participants were. Even though the experienced venture capitalists in the room argued passionately at why they no longer considered the initial public offerings as a relevant ambition for their portfolio companies they were unable to convince an audience composed mainly of start-up entrepreneurs.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.